Skip to content

Vehicle Solution

DRUG12 trials

Sponsors

Cassiopea S.p.A., Cassiopea S.p.A., Allergan, Topica Pharmaceuticals, Meiji Seika Pharma Co., Ltd., 9305-9954 Quebec Inc

Conditions

Alopecia, AndrogeneticAndrogenetic AlopeciaCommon WartsDistal and Lateral Subungual OnychomycosisFemale Pattern BaldnessHypotrichosisOnychomycosisPlaque Psoriasis

Phase 1

Phase 2

Phase 3

Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin
CompletedNCT00907426
AllerganHypotrichosis
Start: 2009-08-31End: 2011-05-31Updated: 2012-09-19
A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.
CompletedNCT02667236
Aclaris Therapeutics, Inc.Seborrheic Keratosis
Start: 2016-01-31End: 2016-10-31Updated: 2018-02-06
A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis
CompletedNCT02667275
Aclaris Therapeutics, Inc.Seborrheic Keratosis
Start: 2016-01-31End: 2016-10-31Updated: 2018-02-06
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
Active, not recruitingNCT05888922
Industrial Farmacéutica Cantabria, S.A.Androgenetic Alopecia, Female Pattern Baldness
Start: 2024-10-17End: 2026-11-16Target: 520Updated: 2026-09-16
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss
CompletedNCT05910450
Cassiopea SpAAlopecia, Androgenetic
Start: 2023-06-21End: 2026-01-26Updated: 2026-06-08
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)
CompletedNCT05914805
Cassiopea SpAAlopecia, Androgenetic
Start: 2023-08-17End: 2025-07-16Updated: 2025-12-22
A 6-Month Phase 3, Multicenter, Prospective, Randomized, Double-Blind, Vehicle-Controlled Study, to Evaluate the Efficacy and Safety of Topically Applied Clascoterone (Cortexolone 17α-Propionate) Solution for the Treatment of Androgenetic Alopecia in Males, Followed by a 6-Month Single-Blind Treatment with Clascoterone or Vehicle BID Solution (SCALP 2)
CompletedCTIS2023-504421-39-00
Cassiopea S.p.A., Cassiopea S.p.A.Androgenetic Alopecia
Start: 2023-11-21End: 2025-07-16Target: 629Updated: 2025-08-19